{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:23:56Z","timestamp":1778239436899,"version":"3.51.4"},"reference-count":83,"publisher":"IOP Publishing","issue":"17","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/iopscience.iop.org\/info\/page\/text-and-data-mining"}],"funder":[{"name":"National Science and Technology Council, Taiwan","award":["NSTC 110-2923-M-009-005-MY3"],"award-info":[{"award-number":["NSTC 110-2923-M-009-005-MY3"]}]}],"content-domain":{"domain":["iopscience.iop.org"],"crossmark-restriction":false},"short-container-title":["Nanotechnology"],"published-print":{"date-parts":[[2024,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Heparins are a family of sulfated linear negatively charged polysaccharides that have been widely used for their anticoagulant, antithrombotic, antitumor, anti-inflammatory, and antiviral properties. Additionally, it has been used for acute cerebral infarction relief as well as other pharmacological actions. However, heparin\u2019s self-aggregated macrocomplex may reduce blood circulation time and induce life-threatening thrombocytopenia (HIT) complicating the use of heparins. Nonetheless, the conjugation of heparin to immuno-stealth biomolecules may overcome these obstacles. An immunostealth recombinant viral capsid protein (VP28) was expressed and conjugated with heparin to form a novel nanoparticle (VP28-heparin). VP28-heparin was characterized and tested to determine its immunogenicity, anticoagulation properties, effects on total platelet count, and risk of inducing HIT in animal models. The synthesized VP28-heparin trimeric nanoparticle was non-immunogenic, possessed an average hydrodynamic size (8.81 \u00b1 0.58 nm) optimal for the evasion renal filtration and reticuloendothelial system uptake (hence prolonging circulating half-life). Additionally, VP28-heparin did not induce mouse death or reduce blood platelet count when administered at a high dose <jats:italic>in vivo<\/jats:italic> (hence reducing HIT risks). The VP28-heparin nanoparticle also exhibited superior anticoagulation properties (2.2\u00d7 higher prothrombin time) and comparable activated partial thromboplastin time, but longer anticoagulation period when compared to unfractionated heparin. The anticoagulative effects of the VP28-heparin can also be reversed using protamine sulfate. Thus, VP28-heparin may be an effective and safe heparin derivative for therapeutic use.<\/jats:p>","DOI":"10.1088\/1361-6528\/ad21a2","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T22:29:40Z","timestamp":1706048980000},"page":"175102","update-policy":"https:\/\/doi.org\/10.1088\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune-stealth VP28-conjugated heparin nanoparticles for enhanced and reversible anticoagulation"],"prefix":"10.1088","volume":"35","author":[{"given":"Hussein Reda","family":"Hussein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-5607","authenticated-orcid":false,"given":"Chia-Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yini","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9899-3159","authenticated-orcid":false,"given":"Chih-Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Tzu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chaun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui Nee","family":"Geo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzita Mohd","family":"Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lik Voon","family":"Kiew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-0894","authenticated-orcid":false,"given":"Chia-Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"266","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"nanoad21a2bib1","first-page":"3","article-title":"History of heparin","author":"Barrowcliffe","year":"2012"},{"key":"nanoad21a2bib2","first-page":"1","article-title":"Heparin: An essential drug for modern medicine","volume":"163","author":"Hao","year":"2019"},{"key":"nanoad21a2bib3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/ph9030038","article-title":"Heparin: past, present, and future","volume":"9","author":"Oduah","year":"2016","journal-title":"Pharmaceuticals"},{"key":"nanoad21a2bib4","first-page":"320","article-title":"Inadvertent overdose of low-molecular-weight heparin in an elderly patient with deep vein thrombosis and acute kidney injury","volume":"69","author":"Al Saleh","year":"2016","journal-title":"Can. J. Hosp. Pharm."},{"key":"nanoad21a2bib5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1525-139X.2010.00770.x","article-title":"Unfractionated heparin for hemodialysis: still the best option","volume":"23","author":"Cronin","year":"2010","journal-title":"Semin. Dialysis"},{"key":"nanoad21a2bib6","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/cncr.22892","article-title":"A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications","volume":"110","author":"Kuderer","year":"2007","journal-title":"Cancer"},{"key":"nanoad21a2bib7","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/jth.12595","article-title":"The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials","volume":"12","author":"Sanford","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"nanoad21a2bib8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/HPC.0b013e3181d29713","article-title":"The use and limitations of unfractionated heparin","volume":"9","author":"Krishnaswamy","year":"2010","journal-title":"Crit. Pathways Cardiol."},{"key":"nanoad21a2bib9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/0167-4889(85)90177-6","article-title":"Binding and endocytosis of heparin by human endothelial cells in culture","volume":"845","author":"B\u00e2rzu","year":"1985","journal-title":"Biochimica et Biophysica Acta (BBA)-Mol. Cell Res."},{"key":"nanoad21a2bib10","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199105303242206","article-title":"Heparin","volume":"324","author":"Hirsh","year":"1991","journal-title":"New Engl. J. Med."},{"key":"nanoad21a2bib11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1055\/s-0038-1648515","article-title":"Heparin binding to plasma proteins, an important mechanism for heparin resistance","volume":"67","author":"Young","year":"1992","journal-title":"Thrombosis Haemostasis"},{"key":"nanoad21a2bib12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/archinte.1994.00420010073009","article-title":"A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin","volume":"154","author":"Levine","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"nanoad21a2bib13","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"New Engl. J. Med."},{"key":"nanoad21a2bib14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1358863X19898253","article-title":"Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management","volume":"25","author":"Hogan","year":"2020","journal-title":"Vascular Med."},{"key":"nanoad21a2bib15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1172\/JCI109661","article-title":"Effect of heparin and heparin fractions on platelet aggregation","volume":"65","author":"Salzman","year":"1980","journal-title":"J. Clin. Invest."},{"key":"nanoad21a2bib16","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/01.ATV.0000137189.22999.3f","article-title":"Heparin-binding domains in vascular biology","volume":"24","author":"Munoz","year":"2004","journal-title":"Arterioscl. Throm. Vas."},{"key":"nanoad21a2bib17","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1182\/blood.V83.11.3232.3232","article-title":"Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4","volume":"83","author":"Kelton","year":"1994","journal-title":"Blood"},{"key":"nanoad21a2bib18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1161\/01.CIR.98.15.1575","article-title":"Low-molecular-weight heparin","volume":"98","author":"Hirsh","year":"1998","journal-title":"Circulation"},{"key":"nanoad21a2bib19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11095-008-9769-y","article-title":"Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin","volume":"26","author":"Bai","year":"2009","journal-title":"Pharm. Res."},{"key":"nanoad21a2bib20","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.2174\/1381612821666150821112808","article-title":"Nanocarriers in improved heparin delivery: recent updates","volume":"21","author":"Das Kurmi","year":"2015","journal-title":"Curr. Pharm. De."},{"key":"nanoad21a2bib21","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1080\/10717544.2022.2111479","article-title":"Human serum albumin-based nanoparticles alter raloxifene administration and improve bioavailability","volume":"29","author":"Yang","year":"2022","journal-title":"Drug Deliv."},{"key":"nanoad21a2bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.00166","article-title":"Recent advances in understanding the protein corona of nanoparticles and in the formulation of \u2018stealthy\u2019 nanomaterials","volume":"8","author":"Rampado","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"nanoad21a2bib23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1006\/viro.2001.0928","article-title":"White spot syndrome virus envelope protein VP28 is involved in the systemic infection of shrimp","volume":"285","author":"van Hulten","year":"2001","journal-title":"Virology"},{"key":"nanoad21a2bib24","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2019.197666","article-title":"VP19 is important for the envelope coating of white spot syndrome virus","volume":"270","author":"Li","year":"2019","journal-title":"Virus Res."},{"key":"nanoad21a2bib25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.virol.2022.10.008","article-title":"Rip it, stitch it, click it: a chemist\u2019s guide to VLP manipulation","volume":"577","author":"Wijesundara","year":"2022","journal-title":"Virology"},{"key":"nanoad21a2bib26","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.1128\/JVI.02505-06","article-title":"Crystal structures of major envelope proteins VP26 and VP28 from white spot syndrome virus shed light on their evolutionary relationship","volume":"81","author":"Tang","year":"2007","journal-title":"J. Virol."},{"key":"nanoad21a2bib27","first-page":"52","volume":"vol 693","author":"Nicoli","year":"1998"},{"key":"nanoad21a2bib28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/0023677217718864","article-title":"Simultaneous detection of multiple pathogens by multiplex PCR coupled with DNA biochip hybridization","volume":"52","author":"Tung","year":"2018","journal-title":"Laboratory Animals"},{"key":"nanoad21a2bib29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.06.041","article-title":"Thrombolysis Following Heparin Reversal With Protamine Sulfate in Acute Ischemic Stroke: Case Series and Literature Review","volume":"28","author":"Ranasinghe","year":"2019","journal-title":"J. Stroke Cerebrovascular Dis."},{"key":"nanoad21a2bib30","first-page":"1291","article-title":"Protamine--antagonist to heparin","volume":"108","author":"Jaques","year":"1973","journal-title":"Can. Med. Assoc. J."},{"key":"nanoad21a2bib31","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood-2009-05-222109","article-title":"Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation","volume":"114","author":"Ni Ainle","year":"2009","journal-title":"Blood"},{"key":"nanoad21a2bib32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1055\/s-0038-1645207","article-title":"Neutralization of enoxaparine-induced bleeding by protamine sulfate","volume":"63","author":"Van Ryn-McKenna","year":"1990","journal-title":"Thrombosis Haemostasis"},{"key":"nanoad21a2bib33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ijsu.2010.11.016","article-title":"Heparin for adhesion prevention: comparison of three different dosages with Seprafilm in a murine model","volume":"9","author":"Kement","year":"2011","journal-title":"Int. J. Surg."},{"key":"nanoad21a2bib34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.imlet.2006.01.004","article-title":"The efficacy of recombinant vaccines against white spot syndrome virus in Procambarus clarkii","volume":"105","author":"Jha","year":"2006","journal-title":"Immunol.y Lett."},{"key":"nanoad21a2bib35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0044-8486(03)00363-6","article-title":"Vaccination trials with Penaeus japonicus to induce resistance to white spot syndrome virus","volume":"229","author":"Namikoshi","year":"2004","journal-title":"Aquaculture"},{"key":"nanoad21a2bib36","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1128\/JVI.78.4.2057-2061.2004","article-title":"Protection of Penaeus monodon against white spot syndrome virus by oral vaccination","volume":"78","author":"Witteveldt","year":"2004","journal-title":"J. Virol."},{"key":"nanoad21a2bib37","doi-asserted-by":"publisher","first-page":"13024","DOI":"10.1021\/jacs.5b07761","article-title":"pH-responsive self-assembly of polysaccharide through a rugged energy landscape","volume":"137","author":"Morrow","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"nanoad21a2bib38","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0950-3536(05)80017-4","article-title":"Pharmacokinetics of heparin and low molecular weight heparin","volume":"3","author":"Boneu","year":"1990","journal-title":"Bailliere\u2019s Clin. Haematol."},{"key":"nanoad21a2bib39","doi-asserted-by":"crossref","first-page":"11182","DOI":"10.3390\/ijms222011182","article-title":"Atypical renal clearance of nanoparticles larger than the kidney filtration threshold","volume":"22","author":"Adhipandito","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"nanoad21a2bib40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF02849851","article-title":"The aPTT assay as a monitor of heparin anticoagulation efficacy in clinical settings","volume":"20","author":"Chen","year":"2003","journal-title":"Adv. Ther."},{"key":"nanoad21a2bib41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1160\/TH06-05-0290","article-title":"Monitoring unfractionated heparin with the aPTT: Time for a fresh look","volume":"96","author":"Eikelboom","year":"2006","journal-title":"Thrombosis Haemostasis"},{"key":"nanoad21a2bib42","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"nanoad21a2bib43","first-page":"59","author":"Zhang","year":"2010"},{"key":"nanoad21a2bib44","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1182\/blood-2010-06-292938","article-title":"Heparin modifies the immunogenicity of positively charged proteins","volume":"116","author":"Chudasama","year":"2010","journal-title":"Blood"},{"key":"nanoad21a2bib45","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"nanoad21a2bib46","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.xphs.2019.10.040","article-title":"Evaluating heparin products for heparin-induced thrombocytopenia using surface plasmon resonance","volume":"109","author":"Zhang","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"nanoad21a2bib47","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"key":"nanoad21a2bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ph10040078","article-title":"Heparin mimetics: their therapeutic potential","volume":"10","author":"Mohamed","year":"2017","journal-title":"Pharmaceuticals"},{"key":"nanoad21a2bib49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1160\/TH13-08-0634","article-title":"Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity","volume":"112","author":"Brandt","year":"2014","journal-title":"Thromb Haemost"},{"key":"nanoad21a2bib50","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1160\/TH16-02-0109","article-title":"Risk factors for heparin-induced thrombocytopenia: Focus on Fcgamma receptors","volume":"116","author":"Rollin","year":"2016","journal-title":"Thromb Haemost"},{"key":"nanoad21a2bib51","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1182\/blood-2011-06-359836","article-title":"Platelet granules: surprise packages","volume":"118","author":"Whiteheart","year":"2011","journal-title":"Blood"},{"key":"nanoad21a2bib52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1182\/blood-2004-04-1544","article-title":"Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia","volume":"105","author":"Rauova","year":"2005","journal-title":"Blood"},{"key":"nanoad21a2bib53","doi-asserted-by":"publisher","first-page":"258S\u201375SS","DOI":"10.1378\/chest.108.4_Supplement.258S","article-title":"Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety","volume":"108","author":"Hirsh","year":"1995","journal-title":"Chest"},{"key":"nanoad21a2bib54","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1182\/blood.V98.8.2442","article-title":"Heparin-induced thrombocytopenia\/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA","volume":"98","author":"Reilly","year":"2001","journal-title":"Blood"},{"key":"nanoad21a2bib55","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1046\/j.1538-7836.2003.00270.x","article-title":"Heparin-induced thrombocytopenia","volume":"1","author":"Chong","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"nanoad21a2bib56","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1182\/blood-2010-03-274969","article-title":"PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model","volume":"117","author":"Reilly","year":"2011","journal-title":"Blood"},{"key":"nanoad21a2bib57","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2011-02-335208","article-title":"Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT","volume":"118","author":"Kowalska","year":"2011","journal-title":"Blood"},{"key":"nanoad21a2bib58","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1182\/blood-2005-08-3122","article-title":"Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications","volume":"107","author":"Rauova","year":"2006","journal-title":"Blood"},{"key":"nanoad21a2bib59","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1749-6632.1971.tb46899.x","article-title":"The kinetics of heparin","volume":"179","author":"Estes","year":"1971","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"nanoad21a2bib60","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt1979253372","article-title":"The biologic half-life of heparin","volume":"25","author":"McAvoy","year":"1979","journal-title":"Clin. Pharmacol. Ther."},{"key":"nanoad21a2bib61","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/cc8924","article-title":"Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial","volume":"14","author":"Robinson","year":"2010","journal-title":"Crit. Care"},{"key":"nanoad21a2bib62","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/s-0038-1642434","article-title":"Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin","volume":"71","author":"Young","year":"1994","journal-title":"Thrombosis Haemostasis"},{"key":"nanoad21a2bib63","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.7326\/0003-4819-119-11-199312010-00008","article-title":"Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty","volume":"119","author":"Anderson","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"nanoad21a2bib64","doi-asserted-by":"publisher","first-page":"e495S\u2013530S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis: american college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"nanoad21a2bib65","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/ckj\/sfu080","article-title":"Anticoagulation in chronic kidney disease patients-the practical aspects","volume":"7","author":"Hughes","year":"2014","journal-title":"Clin. Kidney J."},{"key":"nanoad21a2bib66","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/00313020126304","article-title":"A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin","volume":"33","author":"Ip","year":"2001","journal-title":"Pathology"},{"key":"nanoad21a2bib67","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"nanoad21a2bib68","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"nanoad21a2bib69","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/jth.12592","article-title":"Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia","volume":"12","author":"Joseph","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"nanoad21a2bib70","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/2040622313494987","article-title":"Argatroban in heparin-induced thrombocytopenia: rationale for use and place in therapy","volume":"4","author":"Bambrah","year":"2013","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"nanoad21a2bib71","first-page":"115","article-title":"Bivalirudin anticoagulation for cardiopulmonary bypass: an unusual case","volume":"34","author":"Nikolaidis","year":"2007","journal-title":"Tex Heart Inst J."},{"key":"nanoad21a2bib72","first-page":"105","article-title":"The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT","volume":"1","author":"Koster","year":"2007","journal-title":"Biologics"},{"key":"nanoad21a2bib73","author":"Mahat","year":"2023"},{"key":"nanoad21a2bib74","first-page":"1","article-title":"Citric acid-mediated green synthesis of selenium nanoparticles: antioxidant, antimicrobial, and anticoagulant potential applications","volume":"23","author":"Alhawiti","year":"2022","journal-title":"Biomass Convers. Biorefinery"},{"key":"nanoad21a2bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.598977","article-title":"Rutin-loaded silver nanoparticles with antithrombotic function","volume":"8","author":"Wu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"nanoad21a2bib76","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2021.118124","article-title":"Anticoagulation and antibacterial properties of heparinized nanosilver with different morphologies","volume":"266","author":"Meher","year":"2021","journal-title":"Carbohydrate Polym."},{"key":"nanoad21a2bib77","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/chem.201102926","article-title":"Heparin-coated colloidal mesoporous silica nanoparticles efficiently bind to antithrombin as an anticoagulant drug-delivery system","volume":"18","author":"Argyo","year":"2012","journal-title":"Chemistry"},{"key":"nanoad21a2bib78","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/01.CIR.101.22.2658","article-title":"Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis","volume":"101","author":"Gonze","year":"2000","journal-title":"Circulation"},{"key":"nanoad21a2bib79","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0002-9610(98)00127-5","article-title":"Orally administered heparin for preventing deep venous thrombosis","volume":"176","author":"Gonze","year":"1998","journal-title":"Am. J. Surg."},{"key":"nanoad21a2bib80","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1039\/C4BM00156G","article-title":"Graphene oxide modified with aptamer-conjugated gold nanoparticles and heparin: a potent targeted anticoagulant","volume":"2","author":"So","year":"2014","journal-title":"Biomater. Sci."},{"key":"nanoad21a2bib81","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.2147\/IJN.S172230","article-title":"Low-molecular-weight sulfonated chitosan as template for anticoagulant nanoparticles","volume":"13","author":"Heise","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"nanoad21a2bib82","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.2147\/IJN.S31632","article-title":"Preparation and characterization of polysaccharide-based nanoparticles with anticoagulant activity","volume":"7","author":"da Silva","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"nanoad21a2bib83","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2147\/IJN.S174962","article-title":"Multifunctional PLGA-based nanoparticles as a controlled release drug delivery system for antioxidant and anticoagulant therapy","volume":"14","author":"Lee","year":"2019","journal-title":"Int. J. Nanomed."}],"container-title":["Nanotechnology"],"original-title":[],"link":[{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ad21a2","content-type":"text\/html","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ad21a2\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ad21a2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ad21a2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ad21a2\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ad21a2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ad21a2\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"similarity-checking"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ad21a2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T11:54:25Z","timestamp":1708084465000},"score":1,"resource":{"primary":{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ad21a2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":83,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,2,9]]},"published-print":{"date-parts":[[2024,4,22]]}},"URL":"https:\/\/doi.org\/10.1088\/1361-6528\/ad21a2","relation":{},"ISSN":["0957-4484","1361-6528"],"issn-type":[{"value":"0957-4484","type":"print"},{"value":"1361-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"assertion":[{"value":"Immune-stealth VP28-conjugated heparin nanoparticles for enhanced and reversible anticoagulation","name":"article_title","label":"Article Title"},{"value":"Nanotechnology","name":"journal_title","label":"Journal Title"},{"value":"paper","name":"article_type","label":"Article Type"},{"value":"\u00a9 2024 The Author(s). Published by IOP Publishing Ltd","name":"copyright_information","label":"Copyright Information"},{"value":"2023-11-16","name":"date_received","label":"Date Received","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2024-01-23","name":"date_accepted","label":"Date Accepted","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2024-02-09","name":"date_epub","label":"Online publication date","group":{"name":"publication_dates","label":"Publication dates"}}]}}